Ranked by engagement
Top topics — this week page 6
Ranked by replies, likes and views over this week, with a bonus for topics that reached a marked solution. Engagement is a proxy for usefulness and a poor one; the documentation commons is the better index of what is settled.
314 topics · page 6 of 11
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
How shortages have affected compounding permissions — does this still hold?
How shortages have affected compounding permissions — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. A coverage question with the paperwork…
|
+27 | 31 | 21k | 17h |
|
Reconstituting a multi-strength kit without mixing yourself up — what changed since
On the subject in the title: Reconstituting a multi-strength kit without mixing yourself up — what changed since Working notes rather than a conclusion. Practical question with the units stated, because I…
|
+42 | 46 | 1k | 7h |
|
Athletes in weight-category sports: a different risk calculus
Athletes in weight-category sports: a different risk calculus — setting out what I have, and where I think it stops being reliable. General question, not a request for advice about my own care — I know the…
|
+38 | 42 | 6.6k | 1d |
|
Splitting an overlong document into two
Posting this under the heading it deserves: Splitting an overlong document into two Everything below is what sits behind that. Nominating something for promotion into the documentation commons. The topic in…
|
+30 | 34 | 6.2k | 1d |
|
Revisiting: Mobile reading experience on long topics
Posting this under the heading it deserves: Revisiting: Mobile reading experience on long topics Everything below is what sits behind that. Nominating something for promotion into the documentation commons.…
|
+11 | 15 | 34k | 10h |
|
When a dose reduction is the correct response to a side effect
When a dose reduction is the correct response to a side effect — that is the question, and I have not found it answered plainly anywhere I have looked. A question about technique rather than about dose. I…
|
+38 | 42 | 2.7k | 19h |
|
Fixed versus detachable needles: the trade-offs — does this still hold?
Fixed versus detachable needles: the trade-offs — does this still hold? I have a specific reason for asking rather than idle curiosity, and the context is below. A question about technique rather than about…
|
+8 | 12 | 39k | 15h |
|
Transit times by route, from a logged dataset
Transit times by route, from a logged dataset Writing it up because I had to work it out twice and would rather nobody else did. A logistics question, since the answers here are usually better than anywhere…
|
+34 | 38 | 3.6k | 18h |
|
Coming back to: Telehealth prescribing models in the US
Posting this under the heading it deserves: Telehealth prescribing models in the US Everything below is what sits behind that. Documenting an access outcome, dated, because everything in this category…
|
+26 | 30 | 17k | 17h |
|
PIONEER 6 cardiovascular safety, read as a safety trial rather than an efficacy one
PIONEER 6 cardiovascular safety, read as a safety trial rather than an efficacy one — setting out what I have, and where I think it stops being reliable. Session topic: FLOW ( N Engl J Med , 2024). Please…
|
+25 | 29 | 22k | 1d |
|
Follow-up: The most useful thing you learned here that was not the answer you came for
On the subject in the title: The most useful thing you learned here that was not the answer you came for Working notes rather than a conclusion. Lower-stakes topic, but the sourcing rule still applies if…
|
+30 | 34 | 9.7k | 11h |
|
Revisiting: How this community labels and discusses unrefereed work
Revisiting: How this community labels and discusses unrefereed work Writing it up because I had to work it out twice and would rather nobody else did. I have seen SURMOUNT-OSA ( N Engl J Med , 2024) cited in…
|
+31 | 35 | 7k | 1d |
|
Lipid changes during rapid weight loss: the expected trajectory
Posting this under the heading it deserves: Lipid changes during rapid weight loss: the expected trajectory Everything below is what sits behind that. General question, not a request for advice about my own…
|
+11 | 15 | 34k | 11h |
|
Solubility limits and what a cloudy solution is telling you
Solubility limits and what a cloudy solution is telling you — setting out what I have, and where I think it stops being reliable. A documentation question rather than an analytical one. I have a certificate…
|
+11 | 15 | 34k | 20h |
|
Journal club: semaglutide in MASH, and surrogate endpoints
Posting this under the heading it deserves: Journal club: semaglutide in MASH, and surrogate endpoints Everything below is what sits behind that. Comparing SCALE ( N Engl J Med , 2015) with SURMOUNT-2 (…
|
+24 | 28 | 17k | 15h |
|
Risk-of-bias tools and the judgement they conceal — does this still hold?
Risk-of-bias tools and the judgement they conceal — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. Comparing SURPASS-2 ( N Engl J Med , 2021)…
|
+26 | 30 | 5.8k | 23h |
|
Semaglutide formulation: what is in the licensed product besides the peptide
Semaglutide formulation: what is in the licensed product besides the peptide — setting out what I have, and where I think it stops being reliable. Comparing LEADER ( N Engl J Med , 2016) with SURMOUNT-1 ( N…
|
+29 | 35 | 4.4k | 1h |
|
Reading U-100 graduations, with a conversion table
Posting this under the heading it deserves: Reading U-100 graduations, with a conversion table Everything below is what sits behind that. Practical question with the units stated, because I have seen how…
|
+35 | 41 | 2k | 1d |
|
Sulfonylureas: the interaction most worth taking seriously
Sulfonylureas: the interaction most worth taking seriously Writing it up because I had to work it out twice and would rather nobody else did. Practical question with the units stated, because I have seen how…
|
+4 | 8 | 38k | 6h |
|
A revision dispute resolved on the topic rather than in the history
A revision dispute resolved on the topic rather than in the history Writing it up because I had to work it out twice and would rather nobody else did. Nominating something for promotion into the documentation…
|
+11 | 15 | 40k | 16h |
|
What the GIP component of tirzepatide is thought to contribute, and how confident we can be
What the GIP component of tirzepatide is thought to contribute, and how confident we can be I have a specific reason for asking rather than idle curiosity, and the context is below. Comparing STEP 1 ( N Engl…
|
+16 | 20 | 23k | 19h |
|
What a certificate commits its issuer to — the long version
Asking directly, because I could not find a straight answer: What a certificate commits its issuer to — the long version A documentation question rather than an analytical one. I have a certificate in front…
|
+20 | 26 | 21k | 2d |
|
Why cagrilintide alone is discussed so much less than in combination — does this still hold?
Why cagrilintide alone is discussed so much less than in combination — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. Session topic: SURMOUNT-4…
|
+27 | 31 | 1.2k | 22h |
|
AOD-9604 and the fragment hypothesis, revisited — does this still hold?
The question in the title: AOD-9604 and the fragment hypothesis, revisited — does this still hold? I will give what I have already checked below so nobody repeats it. Comparing FLOW ( N Engl J Med , 2024)…
|
+7 | 11 | 31k | 19h |
|
Travelling with an injectable: documentation and practicalities
Posting this under the heading it deserves: Travelling with an injectable: documentation and practicalities Everything below is what sits behind that. Documenting an access outcome, dated, because everything…
|
+37 | 42 | 2.1k | 1d |
|
Follow-up: UK access routes, dated and sourced
On the subject in the title: UK access routes, dated and sourced Working notes rather than a conclusion. Documenting an access outcome, dated, because everything in this category expires. As of May 2026, in…
|
+10 | 14 | 27k | 2d |
|
Follow-up: The retatrutide phase 2 obesity paper, read closely
The retatrutide phase 2 obesity paper, read closely — setting out what I have, and where I think it stops being reliable. I have seen STEP 4 ( JAMA , 2021) cited in support of a claim I do not think it…
|
+19 | 23 | 16k | 2d |
|
Conditions that change the calculus rather than forbidding it
Conditions that change the calculus rather than forbidding it Writing it up because I had to work it out twice and would rather nobody else did. Asking about a population rather than about a person. The…
|
+28 | 32 | 6.1k | 1d |
|
Composite endpoints and the component doing the work
Composite endpoints and the component doing the work Writing it up because I had to work it out twice and would rather nobody else did. I have seen SURPASS-4 ( Lancet , 2021) cited in support of a claim I do…
|
+3 | 7 | 33k | 13h |
|
A calculator that gives a right answer to the wrong question
Posting this under the heading it deserves: A calculator that gives a right answer to the wrong question Everything below is what sits behind that. I would like to understand what this number means before I…
|
+32 | 36 | 1.9k | 17h |